Welcome to the EDGE Newton-2 Study!

Edge Therapeutics Logo

The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical trial Newton-2 (Protocol #EG-01-1962-03) evaluating a new formulation to treat aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that assessors at the clinical sites are well versed on the neurologic outcome assessments in this trial. We are providing online training course, assessment tools, and informational updates. Please see the menu for these materials.

Additionally, please feel free to contact us with any questions you may have. Meanwhile, we look forward to working with you!

297 Hits

CLEAR-III Day-180 Results Presented at International Stroke Conference

CLEAR-III was all the talk at this year's International Stroke Conference (ISC). We had a number of presentations and posters discussing the Day-180 results of this six-year international multicenter trial exploring the delivery of alteplase, a thrombolytic ("clot buster"), via the extraventricular drain in patients with intraventricular hemorrhage (IVH). Thank you to all the clinical site staff and patients that contributed to this trial. There is alway more research needed when dealing with such a serious condition, but the knowledge gained on this project has been invaluable and will shape the future direction of future research for years to come.

Interview with Dr. Daniel Hanley, Co-principal Investigator for CLEAR-III

Photos of the team attending ISC

ISC Media Release

Abstracts and Slides  Dr. Hanley's presentation was LB12. Dr. Issam Awad's presentation was LB13

 Additionally, there have been lots of new articles about the CLEAR III results:

Continue reading
1172 Hits

MISTIE III Safety Forum

Please save the date for our

Quarterly MISTIE III Safety Forum

To be held via webinar

Wednesday, April 6th at 1-2pm EDT


Registration link: https://attendee.gotowebinar.com/register/6875213595780426243 


Principal Investigator and M3 Neurosurgeon attendance is required.


Hemodialysis Use in MISTIE III Subjects

Vascular Defect Screening in MISTIE III Subjects

Update from our Surgical Centers:  Where We Stand Surgically 

Click here for a video recording of the Safety Forum.




782 Hits

MISTIE III - 4th Thursday 9am Monthly Webinars Canceled

We have canceled the MISTIE III 4th Thursday Monthly Webinars.

To attend our MISTIE III Monthly Webinars, please join us on the 1st Tuesday of every month at 8am or 2pm Eastern. The registration links for our Tuesday webinars are provided below. Once registered, details of the webinar will be e-mailed to you.

8am: https://attendee.gotowebinar.com/register/6338871822802146305
2pm: https://attendee.gotowebinar.com/register/2492870308800050689

In the event you cannot attend our Tuesday webinar, please visit our website at www.braininjuryoutcomes.com for recordings.

Should you have any questions, please contact Amanda Bistran-Hall at This email address is being protected from spambots. You need JavaScript enabled to view it.
'; document.getElementById('cloak88370').innerHTML += ''+addy_text88370+''; //--> .

707 Hits

AVERT Pilot Trial Recruiting at all study sites

UPDATE - St. Joseph Mercy Hospital in Michigan began PILOT trial recruitment on 1/4/16 joining OSF UI in Peoria, IL and JH Bayview in Baltimore, MD.  All study sites are recruiting patients for the PILOT Trial.  

592 Hits